📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Verastem

1.1 - Company Overview

Verastem Logo

Verastem

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of biopharmaceutical therapies targeting RAS/MAPK pathway–driven cancers, developing avutometinib, a RAF/MEK clamp designed to block RAF and MEK signaling in the RAS pathway, and defactinib, a FAK inhibitor used with avutometinib to block compensatory FAK activation and enhance tumor growth blockade.

Products and services

  • Avutometinib + Defactinib Combination Regimen: A combination regimen that simultaneously clamps RAF/MEK and inhibits compensatory FAK activation, enhancing tumor growth blockade in RAS/MAPK pathway-driven cancers
  • Avutometinib: A pathway-specific RAF/MEK clamp that blocks RAF and MEK signaling within the RAS pathway, engineered to treat RAS pathway-driven cancers
  • Defactinib: A mechanism-based FAK inhibitor used alongside avutometinib to block compensatory FAK activation, enhancing tumor growth blockade

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Verastem

Pheon Therapeutics Logo

Pheon Therapeutics

HQ: United Kingdom Website
  • Description: Provider of antibody-drug conjugate (ADC) programs for difficult-to-treat cancers. Offerings include PHN-010, an ADC targeting a transmembrane protein over-expressed in multiple solid tumors with low expression in healthy tissues; development of first-in-class solid tumor programs with in vivo proof of concept; and proprietary payloads to overcome resistance, featuring novel modes of action and tunable potency.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Pheon Therapeutics company profile →
Elevation Oncology Logo

Elevation Oncology

HQ: United States Website
  • Description: Provider of precision medicines as a clinical-stage biopharmaceutical company, developing EO-3021, an antibody-drug conjugate targeting Claudin 18.2 for advanced/metastatic solid tumors, particularly gastric and gastroesophageal junction adenocarcinoma, and Seribantumab, an anti-HER3 monoclonal antibody for NRG1 fusion-positive tumors; conducts clinical trials and offers compassionate use.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Elevation Oncology company profile →
CatalYm Logo

CatalYm

HQ: Germany Website
  • Description: Provider of immunotherapies for cancer, developing Visugromab (CTL-002), a monoclonal antibody targeting GDF-15 to counteract immunosuppression in the tumor microenvironment and enhance immune cell infiltration against solid tumors, and running GDFATHER-2 Phase 2 trials evaluating Visugromab with nivolumab in patients relapsed or refractory to anti-PD-1/PD-L1 therapy.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full CatalYm company profile →
Gradalis Logo

Gradalis

HQ: United States Website
  • Description: Provider of personalized cancer immunotherapy leveraging patients' own genetically modified tumor cells to enhance immune recognition and killing through its Vigil platform, and of clinical trials evaluating the safety and efficacy of Vigil across cancer types, including ovarian cancer and Ewing’s sarcoma.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Gradalis company profile →
Umoja Biopharma Logo

Umoja Biopharma

HQ: United States Website
  • Description: Provider of next-generation immunotherapies intended to combat cancer.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Umoja Biopharma company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Verastem

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Verastem

2.2 - Growth funds investing in similar companies to Verastem

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Verastem

4.2 - Public trading comparable groups for Verastem

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Verastem

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Verastem

What does Verastem do?

Verastem is a provider of biopharmaceutical therapies targeting RAS/MAPK pathway–driven cancers, developing avutometinib, a RAF/MEK clamp designed to block RAF and MEK signaling in the RAS pathway, and defactinib, a FAK inhibitor used with avutometinib to block compensatory FAK activation and enhance tumor growth blockade.

Who are Verastem's competitors?

Verastem's competitors and similar companies include Pheon Therapeutics, Elevation Oncology, CatalYm, Gradalis, and Umoja Biopharma.

Where is Verastem headquartered?

Verastem is headquartered in United States.

How many employees does Verastem have?

Verastem has 1,000 employees 🔒.

When was Verastem founded?

Verastem was founded in 2010 🔒.

What sector and industry vertical is Verastem in?

Verastem is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Verastem

Who are the top strategic acquirers in Verastem's sector and industry

Top strategic M&A buyers and acquirers in Verastem's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Verastem?

Top strategic M&A buyers groups and sectors for Verastem include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Verastem's sector and industry vertical

Which are the top PE firms investing in Verastem's sector and industry vertical?

Top PE firms investing in Verastem's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Verastem's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Verastem's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Verastem's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Verastem include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Verastem's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Verastem?

The key public trading comparables and valuation benchmarks for Verastem include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Verastem for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Verastem with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Verastem's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Verastem with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Verastem's' sector and industry vertical?

Access recent funding rounds and capital raises in Verastem's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Verastem